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1INTRODUCTION:
Neuro hormonal and pro-inflammatory cytokine activation in chronic
heart failure , favors development of anemia of chronic disease with
defective iron utilization.
2AIM OF THE STUDY:
To know the prevalence of anaemia of chronic disease in chronic heart
failure patients by using iron studies.
3METHOD:
50 patients known to suffer from CHF due to either left ventricular
systolic or diastolic dysfunction and were regularly attending review op will
be selected and the iron study will be conducted.
4INCLUSION CRITERIA:
 Patients with stable clinical condition (absence of physical findings of
congestion)
 Haemoglobin concentration <13 g/dl in males and <12 g/dl in females
 Age between 45 to 64 yrs
EXCLUSION CRITERIA
 New cases of heart failure defined by duration of symptoms <6
months
 Renal dysfunction (serum creatinine >1.2 mg/dl)
5METHODOLOGY
Informed consent will be obtained for taking part in this study. Patient
demographic information, medical history including diagnosis of CHF will
be obtained from the patient medical records using predesigned data
collection forms.
Investigatons included are complete blood count, peripheral smear,
renal function test, ESR, CRP, serum ferritin and total iron binding capacity.
6STUDY DESIGN:
Prevalence Study
SAMPLE SIZE
All cases of chronic heart failure of age 45 to 64 years came for review
op in Medicine Department were evaluated
STUDY PERIOD
JULY 2015 – JUNE 2016
7REVIEW
OF
LITERATURE
8REVIEW OF LITERATURE:
ANEMIAS DUE TO REDUCED PROLIFERATION:
 Red cells are normocytic and normochromic
 The retic index is less than 2 to 2.5
This includes the following:
 Very early stages of iron deficiency anemic state without
hypochromic and microcytosis
 Inflammatory conditions either acute or chronic
 Kidney problems
 Protein deficiency and decreased metabolic conditions
 Endocrine problems
 Marrow destruction leading to anemia
Abnormal metabolism of iron is caused by chronic inflammation. This leads
to abnormal iron utilization.
This condition is the most common in this category.
There is abnormal response to erythropoietin is also present in this.
9Metabolism of iron:
Iron is important in the formation of hemoglobin. It is also needed for
the other essential elements in our body like myoglobin, cytochromes,
cytochrome oxidase, catalase, peroxidase.
It is required to know the way by which iron is used in the body.
The total amount of iron in body is nearly 4 to 5 grams. 65% is in the
hemoglobin form.
4% is found in the form of myoglobin. 1% is in the form of various
heme containing compounds useful for various intracellular oxidation
processes. 0.1% is combined with transferrin in the plasma of blood.
15 to 30% are stored for the purpose of later use. The storage sites are liver
parenchyma, reticulo endothelial cells. The storage form is ferritin.
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Iron transport and storage:
Iron absorbed from the diet and released from stores circulates in the
plasma bound to transferrin, which is the iron transport protein.
Transferrin is a bilobed glycoprotein having two iron binding sites.
Transferrin that carries iron exists in two forms—
 monoferric (one iron atom) or
 diferric (two iron atoms).
The turnover of transferrin-bound iron is very rapid—typically 60–90
min.
Because almost all of the iron transported by transferrin is delivered
to the erythroid marrow, the clearance time of transferrin-bound iron  is
affected by iron level in the plasma and the erythroid activity of bone
marrow.
In iron deficiency state half life of iron is small like 10 to 15 minutes
only.
If the red cell production is depressed, iron levels are increased and
the clearance half life is increased as well to many hours. There is six to eight
times per day turn over of transferring bound iron.
The normal iron store in body is 80 to 100 g/dl. Iron to transferring pool is
20 to 24 mg/day.
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Internal iron exchange
Approximately 80% of iron passing through the plasma transferrin
pool is recycled from broken-down red cells. Absorption of approximately
1 mg/d is required from the diet in men, and it is 1.4 mg/d in women .
The iron use is not needed till the 20 to 60 percent saturation of
transferring is maintained and also the the red cell production is not
increased. In cases of inadequate iron from food, loss of excess blood,
defective iron absorption from intestine there can be mobilization of upto 40
milligram per day of iron.
The complex of iron and transferring will be in circulation until they
meet the particular transferrin receptors which are present in the erythroid
cells of bone marrow. There is higher affinity for transferrin receptors by the
differic form of transferring. There is poor affinity to transferrin receptors
by the apotransferrin.
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In our body, all the cells are having transferring receptors in some time
in their development.
But the developing erythroblast cells have maximum number of
receptors in the range of 3 lakh to 4 lakh per cell.
This complex of iron and transferring meets the transferrin receptor
on the surface of cells.
They are taken inside the cells through clathrin coated pits. These are
released into the endosomes which are acidic. The iron is released in the
acidic medium for the synthesis of heme.
The receptor and transferring complex is brought back to surface. The
transferrin is let back to blood circulation. Receptors are restored to the cell
surface.
Some of the complex of transferrin and receptor  protein are circulated
in plasma and can be measured.
The excess iron in the erythroid cells will be binded to apoferritin and stored
as ferritin.
This same process also takes place in other cells of body. In liver cells,
it is either stored or used for other heme containing enzymes.
Hemoglobin with iron is released from bone marrow to the circulation.
15
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 The average life span of red blood cells is 120 days
 Around 0.8 to 1 percent of them must be turned over per day
 One milligram of elemental iron is present in one ml of RBC
 20 milligram of elemental iron is lost everyday in the red cell aging
process
 This must be replaced daily from our diet
 One milligram of elemental iron must be absorbed by male daily and
it is around 1.4 milligram per day in case of adult women
 In case of anemia, more iron is to be needed for the increased red cell
production
 Here the demand of iron is increased many folds
In cases of extravascular lysis of red cells, iron from the cells are again
used in the synthesis of hemoglobin. But in cases of intravascular hemolysis,
iron from the stores must be mobilized  and hence the rate of RBC production
is limited.
The hemoglobin production is reduced when the iron mobilization is low.
This leads to hypoproliferation and the cells become hypochomic and
microcytic.
The loss of blood and lysis of red cells pose high need on iron supply. In
the diseases causing chronic inflammation, iron could not be released from
iron stores effectively and hence this leads to decreased serum iron level.
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Iron balance:
 The sources of iron to our body are from
 Absorption from food we take
 Iron containing medications
 Parenteral iron injections
 Blood transfusions
 The methods by which iron is let out of our body are blood loss
through
 GI blood loss
 Menstrual blood loss
 Other blood losses
 Loss of epithelial cells of GIT, GUT, skin
The margin between the need of iron and its availability through
absorption are narrow in young infants and females in childbearing age
group. This is the reason for the high prevalence of iron deficiency anemia
in the population all over the world.
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Iron from diet:
 Each 1000 kilocal of diet has average of six milligram of elemental
iron.
 Heme iron is a form of iron has good bioavailability. Common food
having this is meat.
 Non heme iron has poor bioavailability which is seen in vegetarian
diet.
 Twenty percent of iron is absorbed from meat
 Only five to ten % can be from vegetarian diet
 Vegetarian diet has tannates, phythates, phosphates which all will
reduce the iron absorption
 Availability of iron in some foods as compared with equivalent of
amount of ferrous salt are
 Vegetarian diet – 1/20
 Egg – 1/8
 Liver – ½
 Heme iron – ½ to 1/3
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Absorption of iron:
 the absorption of iron is a highly regulated thing
 it takes place highly in the proximal part of small intestine
 this is increased by the acid medium in the stomach
 this acidity keeps iron iron in soluble form
 in the brush border cells, ferric form of iron is converted to ferrous
form by the enzyme ferrireductase
Transport of iron:
There is a protein called divalent metal transporter type 1. This is
a cation tranporter.
Transport of iron across membrane takes place through this protein.
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REGULATION OF IRON ABSORPTION:
 there is an iron regulatory hormone called hepcidin
 it negatively regulates ferroportin
 hephaestin is a ferro-oxidase which oxidizes iron to ferric form
 ferric form of iron combine with transferring
 in anemic patients with defective red cell production, there is
increased absorption
 this causes iron overload and tissue destruction
 in iron deficient states, hepcidin level is low and iron is absorbed well
 exactly the opposite occirs in secondary iron overload
 in cases of ingestion of iron more than needed leads to less absorption
but the amount in body raises. Plasma iron exceeds the transferrin
binding capacity. Free iron level raises. This causes damage to vital
organs of body like pancreas, heart etc
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IRON DEFECIENCY ANEMIA :
 It is the most common cause of anemia worldwide
 Iron deficiency is the most common form of malnourishment
 Fifty percent of anemia cases are due to iron deficiency
 Developing countries in asia and Africa bear the greatest number of
cases
FIRST STAGE OF IRON DEFECIENCY:
 This state is called negative balance of iron
 the absorption rate of iron is less than the need for iron
 this situation is seen in some conditions like
 loss of blood from any cause
 pregnant state
 increased growth during adolescent period
 deficient iron intake in diet
 In this stage if the blood loss due to any source occurs, the amount of
iron absorbed cannot meet the need
 Hence, iron should be transferred from iron stores to meet this extra
need
 So the storage form of iron, ferritin decreases
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 Stainable iron in bone marrow also reduces
 When the iron stores are adequate then the serum level of iron and the
Total iron binding capacity remains within normal levels
 The red blood cell structure and their indices also remain normal
IRON DEFECIENCY STATE:
 When the stores of iron are depleted the following changes occur
 There will be reduction in serum iron
 TIBC levels are elevated
 There is absence of bone marrow iron stores
 Serum ferritin is greatly reduced like less than fifteen gram per
liter
 If the serum iron is within normal range, hemoglobin synthesis is
normal
 But if the transferring saturation falls below 15 to 20 percent,
hemoglobin production also decreases
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PERIPHERAL SMEAR IN IRON DEFICIENCY ANEMIA:
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 This state is called the iron deficiency state
 The peripheral smear study shows the following features:
 Initially microcytic cells appear and then only hypochromic
cells begins to appear
 In severe anemia poikilocytic cells, pencil shaped cells, target
cells will be present
 The hemoglobin and hematocrit values tend to fall
 Transferrin saturation will become below ten to fifteen percent
 Initially the bone marrow study shows decreased proliferation
 On chronic iron deficient states, bone marrow shows erythroid lineage
hyperproliferation
IRON DEFECIENCY – CAUSES:
1. Increased iron demand
2. Increased iron loss
3. Decreased iron intake/absorption
1.Increased Iron demand:
 Adolescent and infant age group growth spurts
 Pregnant women
 Erythropoietin treatment
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2.Increased Iron Loss:
 blood loss for long periods
 Menstrual bleeding
 blood loss acutely
 Blood donation
 Phlebotomy as a treatment in cases of polycythemia vera
3.Decreased Iron Intake/Absorption:
 Decreased dietary intake
 Malabsorptive states
 Malabsorption due to surgery, Eg: postgastrectomy
 Inflammatory disorders, acute or chronic
The conditions leading to iron deficient states are any growth spurt
periods, women in pregnant state, any h/o bleeding from any source. Any
adult men having iron deficiency anemia it is due to GIT bleeding till proven
differently.
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Clinical features:
Symptoms:
 Easy fatiguability
 Palpitation
 Breathlessness
 Chestpain
 Generalized weakness
 Decreased exercise capacity
Signs:
 Skin and mucosal pallor
 Fissures along angle of mouth
 Flattening and spooning of nails
Iron Studies:
 The iron level in serum is the amount of iron complexed to transferrin
and circulating in circulation.
 The normal level of serum iron is 50 to 150 gram/dl
 Circulating transferrin is indirectly measured by TIBC.
 The normal level of TIBC is 300 to 360 gram/dl.
 Serum iron x 100 ÷ TIBC is the formula to calculate transferrin
saturation.
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 The normal value is between 25 and 50 percent
 Less than 20 percent tells iron deficiency
 Iron complexed with transferring is given to non-erythroid cells if the
saturation is more than 50 percent. This will lead to iron overload on
extended period of time.
Protection against free iron:
 The cells are more liable to free iron hence free iron is injurious to
cells
 Hence the body has some protection in the form of ferritin,
hemosiderin to them the free iron is complexed within the cells
 The free ferrous form of iron is combined with apoferritin and be in
ferric form
 When the ferritin load raises within cells of RE, then proteins
aggregate to form hemosiderin
 This form of stored iron can be used when needed
 But iron in hemosiderin form is not easily available for usage
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Serum ferritin:
 The serum ferritin thus is an indirect measure of our body stores of
iron under normal conditions
 In adult male the normal value is 100 gram/litre
 In adult female it is 30 gram/liter
 Values less than fifteen indicates absence of bone marrow storage of
iron
BONE MARROW IRON STORES EXAMINATION:
 Bone marrow aspiration or biopsy is used for staining iron in marrow
 But serum ferritin is a good  method and nowadays this is used instead
of marrow iron staining
 The importance of marrow iron staining is that the delivery of iron to
the newly developing erythroid cells is given by this method
 The developing erythroblast cells are called sideroblasts
 Usually, 20 to 40 percent of them will stain for ferritin granules and
this indicates that the iron stores is in excess
 In conditions were release of iron from their stores are blocked, then
RE cells will have detectable iron stain and there will be absence of
sideroblasts
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NORMAL IRON STAIN                       ABSENT IRON STAIN
PROTOPORPHYRIN LEVEL IN RED BLOOD CELLS:
 Protoporphyrins are produced in between the heme synthesis pathway
 In situations were heme synthesis is reduced, these protoporphyrins
will accumulate inside the red blood cells
 Hence, it is an indirect evidence of decreased hemoglobin synthesis
and less iron supply to the early progenitors
 Their normal values are less than thirty gram per dl of red blood cells
 It is more than 100 in iron deficiency states
 It is also raised in lead poisoning
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Transferrin receptor protein level in serum:
 All cells in body have transferring receptors but the erythroid cells
have in highest numbers
 These proteins are released inside the circulation
 Hence they indirectly denote the marrow erythroid mass in total
 Their normal levels in blood as detected by immunoassay is 4 to 9
gram per liter
 Thus it is useful in differentiating iron deficient anemia and anemia
due to chronic inflammation
 This is used along with serum ferritin
Differential Diagnosis for iron deficiency anemia:
There are 3 differential diagnosis . they are:
1. the thalassemias:
 inherited lesion in globin chain of hemoglobin
 here the serum iron and transferrin saturation  will be normal or
increased
 RDW – red cell distribution width index is usually less which
will be high in iron deficiency states
31
2. Anemia of chronic inflammation:
 There will be a big confusion to differentiate between iron
deficiency states and this condition
 Here the peripheral smear shows normocytes and normochrome
cells
 The level of ferritin is usually normal or raised
 Both the transferrin saturation percent and TIBC levels are less
than normal values
3. Myelodysplastic syndromes:
 Peripheral blood picture shows microcytes and hypochromic cells
 In this condition, hemoglobin cannot be produced properly and
there will be mitochondrial disturbances
 Hence iron cannot be complexed into heme properly
 So the iron storage are either normal or even more than normal
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Iron deficiency anemia - Treatment:
The treatment of iron deficient states is based on the disease which leads to
it and how long the disease is present.
Some Conditions are:
 Patients who are aged and having CVS problems may need
transfusion to correct the anemia
 If the patient is of earlier age group with mild to moderate anemia,
oral or parenteral iron can be used. The cause of anemia must be
delineated.
 In cases like pregnancy, growth spurt periods, dietary deficiency of
iron intake treatment with iron orally is sufficient
 The cause of iron deficiency must be searched in all cases using
appropriate tests in cases like hereditary diseases, inadequate
absorption, reason for loss of blood
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THERAPEUTIC OPTIONS:
1.RED BLOOD CELL TRANSFUSION:
 Either whole blood or packed cells are transfused for those who are
meeting the result of anemia
 In cases of increased and ongoing blood loss this is the option
 In persons with CVS defects with severe anemia transfusion of packed
cells needed
 Mainly this is to stabilize the patient and thereafter other options of
anemia correction are sought
 It becomes the source of iron and can be used for reuse
 This is mainly used in acute conditions were clinical condition is acute
to correct
 Minor and major side effects to the reaction of blood products may be
there
 Blood borne infections are concern in this option
 Volume overloaded persons should be monitored closely while
transfusion
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ORAL IRON THERAPY:
 The route of administration preferred is oral iron  administration
 Dissociable ferrous salts are inexpensive
 They have high iron content and are better absorbed than the ferric
salts when given in high doses
 Gastric irritation and constipation are proportional to the amount
administered
PREPARATIONS:
 FERROUS SULPHATE – hydrated salt 20% iron and dried salt 32%
iron. It is cheapest. It has metallic taste.
 FERROUS GLUCONATE – 12% iron
 FERROUS FUMARATE – 33% IRON. It is less water soluble than
ferrous sulphate. It is tasteless.
 COLLOIDAL FERRIC HYDROXIDE – 50% iron
 Some other forms are ferrous succinate, iron chloride citrate, iron
calcium complex, ferric ammonium citrate, ferrous ammoniate.
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 The elemental iron and not the quantity of iron compound should be
taken into account
 Sustained release preparations are more expensive and not rationale
 A total of 200 mg of elemental iron is given daily in 3 divided dosage
 In children and infants dose is 3 to 5 mg/kg
 Prophylactic dose is 30 mg per day
 Much better absorption takes place when it is taken in empty stomach
SIDE EFFECTS:
 They are common at therapeutic doses and are related to elemental
iron content
 It differs among individuals
 They are
 Epigastric pain, bloting,
 colic, constipation
 Heartburn
 Nausea, Vomiting
 Teeth staining, Metallic taste
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PARENTERAL IRON THERAPY:
INDICATIONS ARE
 When oral iron is not tolerated
 Failure to absorb normally. Eg., malabsorption, IBD, chronic
inflammatory diseases
 Non-compliance of oral iron
 Severe anemia
 Chronic bleeding
 Along with EPO
The total iron requirement of the patient:
Iron requirement in mg = 4.4 * body weight in KG * Hb deficit in g/dl
This formula includes iron needed for replenishment of iron stores too
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The preparations for parenteral use are:
 Iron dextran: it is a high molecular weight colloidal solution. It ha s50
mg elemental iron per ml. it can be used either im or iv
 Iron sorbitol citric acid: it is a low molecular weight preparation. 50
mg iron is in 1 ml. it is used as im alone
INTRAMUSCULAR ROUTE:
 Given deeply in the gluteal region using Z track method to avoid
staining. It is given 2 ml daily or on alternate days
INTRAVASCULAR ROUTE:
 2 ml can be injected per day slowly over 10 minutes
 Prior test dose to be given
 Otherwise total dose calculated is diluted in 500 ml saline and infused
over 6 to 8 hours
38
Side effects:
 Local:
 Pain at im site
 Pigmentation of skin
 Sterile abscess
 Systemic:
 Fever
 Headache
 Joint pain
 Palpitation
 Chestpain
 Breathlessness
 Lymph node enlargement
 Metallic taste
 Anaphylactoid reaction
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OTHER ANEMIAS DUE TO REDUCED PROLIFERATION:
There are four conditions placed in this list: they are,
(1) diseases causing chronic inflammation,
(2) kidney damage,
(3) nutritional deficient states and some hypometabolic  endocrine disorders
(4) damage to the bone marrow
 In these conditions, there will be inadequate erythropoietin response
to the grade of anemia present
 There will be decreased iron reutilization
 Hence for the stimulation there is no adequate response by bone
marrow
 Due to the less EPO response to the stimulation, the reticulocyte
response also low in the peripheral blood smear
 But in iron deficiency states or conditions with bone marrow damage,
there will be adequate EPO will be present
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Anemia due to Inflammation:
This includes the following conditions:
 Acute or chronic inflammation,
 infections,
 Injury to tissues,
 Due to pro-inflammatory cytokines released in diseases like
malignancy
This condition is the most common differential diagnosis of iron
deficiency states.
Here the iron stores are not low. But iron transport to bone marrow is
impaired.
Hence the following features are observed:
 serum iron is less,
 high red blood cell protoporphyrin level,
 Hypo-proliferative bone marrow,
 Saturation of transferrin at the level of 15–20%, and
 serum ferritin is high or normal.
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PERIPHERAL SMEAR IN ANEMIA OF CHRONIC DISEASE
42
PATHOGENESIS :
 the blood level of serum ferritin is grossly elevated in this condition
due to inflammation
 this mainly distinguishes it from iron deficient states were ferritin is
depressed
 the mediators of this process are interleukins mainly one, interferons,
tumor necrosis factors, hepcidin
The mechanisms by which they are producing anemia are:
 they all are bone marrow suppressors
 they decreases the response of marrow to EPO
 hepcidin causes less iron absorption and reduced iron release
from the stores
Hence there are plenty of iron stores present in the patient but these could
not be used for the effective marrow production of erythroid cells.
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Special condition:
 in some of the patients both the conditions of iron deficiency and
anemia due to inflammation coexist.
 In early stages the blood smear shows normocytes and normal
chromic cells
 But if some blood loss associated with the chronic diseases like TB
and malignancy, the blood picture shows microcytes and
hypochromic cells
 In this situation, bone marrow iron stain is useful to note the iron
defecits
 In this condition, when iron is given the anemia due to iron deficiency
gets corrected but anemia due to inflammation remains the same
 There can be decrease in hemoglobin value of 2 to 3 g/dl in one or two
days because of the lysis of the aging red cells
 This is due to the effect of cytokines and fever which pressurize the
aging cells with defective cell membrane
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Anemia due to Chronic Kidney Disease :
 The patients of CKD suffer from anemia too
 This is due to reduced marrow erythroid production
 This results due to failure of EPO production from the damaged
kidneys and also due to lesser survival of red blood cells
 Usually the degree of anemia is well correlated with the stage of CKD
 The peripheral picture shows normocytes and normochromic cells
 Reticulocyte count is less in this condition
 The iron studies show normal serum iron level, TIBC & ferritin
 In acute kidney injury there is no strong correlation between the
anemia degree and the kidney function
 In CKD patients on dialysis have some blood loss and hence iron
deficiency also be there. Hence iron must be given in them to get good
EPO therapy response
45
Treatment of  Anemia due to reduced proliferation:
 in some cases when the underlying  disease is corrected the
hemoglobin level may be restored to normal level
 but in many chronic cases like chronic kidney disease, malignancy,
chronic inflammatory diseases symptomatic treatment must be
provided
There are two options available for this :
 red blood cell transfusion
 erythropoietin therapy
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TRANSFUSION:
 one unit of packed cell transfusion increases hemoglobin level by one
gram/dl
 liberal use of transfusion in intensive care units has resulted in
increased mortality and morbidity
 hence rational use is needed
 if there is no hypoxia of tissues conservative management is needed
rather than transfusion
 in patients without any cardiovascular or lung compromise will
tolerate hemoglobin above 8 gram/dl. They donot need treatment
above this range
 but in patients with other system compromises their hemoglobin to be
maintained above 11 gram/dl
 complications associated with transfusion are already discussed
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ERYTHROPOIETIN (EPO) THERAPY:
 it is a sialoglycoprotein hormone produced by peritubular cells of the
kidney
 it is essential for the normal erythropoiesis
 it is secreted in response to anemia and hypoxia
Actions:
 stimulates proliferation of colony forming cells of erythroid series
 induces hemoglobin formation and erythroblast maturation
 releases reticulocytes in the circulation
 EPO receptor is a JAK-STAT-kinase binding receptor that alters
phosphorylation of intracellular proteins
 This activates transcription factors to gerulate gene expression
 The recombinant human erythropoietin is injected by iv or sc
 Its plasma half-life is 6 to 10 hours
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USE:
 The main indication is anemia of chronic renal disease
 25 to 100 U sc or iv given 3 times a week
 Maximum dose is 600 U/kg/week
 This improves quality of life
 The dose can be reduced by about 30% in sc injections than iv route
 Anemia in AIDS patients treated with zidovudin
 Cancer chemotherapy induced anemia
 Preoperative increased blood production for autologous transfusion
during surgery
SIDE EFFECTS:
 These are related to sudden increase in hematocrit, blood viscosity and
peripheral vascular resistance.
 Increased clot formation in A-V fistula, hypertensive episodes,
sometimes seizures
 Flu like symptoms may occur in some patients lasting 2 to 4 hours
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RESULTS
GENDER DISTRIBUTION IN ANEMIA OF CHRONIC DISEASE:
Gendera
16 51.6 51.6 51.6
15 48.4 48.4 100.0
31 100.0 100.0
Male
Female
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
GROUP = Anemia of Chronic Diseasea.
14.4
14.6
14.8
15
15.2
15.4
15.6
15.8
16
Male Female
16
15
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GENDER DISTRIBUTION IN IRON DEFECIENCY ANEMIA:
Gendera
10 52.6 52.6 52.6
9 47.4 47.4 100.0
19 100.0 100.0
Male
Female
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
GROUP = Iron Defeciency Anemiaa.
8.4
8.6
8.8
9
9.2
9.4
9.6
9.8
10
Male Female
10
9
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MILD LV DYSFUNCTION:
GROUPa
5 55.6 55.6 55.6
4 44.4 44.4 100.0
9 100.0 100.0
Anemia of Chronic
Disease
Iron Defeciency Anemia
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Severity of LVD = Milda.
0
1
2
3
4
5
Anemia of Chronic Disese Iron Defeciency Anemia
5
4
Frequency
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MODERATE LV DYSFUNCTION:
GROUPa
18 62.1 62.1 62.1
11 37.9 37.9 100.0
29 100.0 100.0
Anemia of Chronic
Disease
Iron Defeciency Anemia
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Severity of LVD = Moderatea.
0
5
10
15
20
Anemia of Chronic Disese Iron Defeciency Anemia
18
11
Frequency
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SEVERE LV DYSFUNCTION:
GROUPa
8 66.7 66.7 66.7
4 33.3 33.3 100.0
12 100.0 100.0
Anemia of Chronic
Disease
Iron Defeciency Anemia
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
Severity of LVD = Severea.
0
1
2
3
4
5
6
7
8
Anemia of Chronic Disese Iron Defeciency Anemia
8
4
Frequency
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MEAN FERRITIN:
Group Statistics
31 296.6774 123.60755 22.20057
19 88.0000 139.72513 32.05514
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ferritin
N Mean Std. Deviation
Std. Error
Mean
296.6774
88
0
50
100
150
200
250
300
350
Anemia of Chronic
Disese
Iron Defeciency
Anemia
Mean FERRITIN
Anemia of Chronic Disese
Iron Defeciency Anemia
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MEAN FERRITIN IN MILD LV DYSFUNCTION:
Group Statisticsa
5 354.4000 87.81116 39.27035
4 20.2500 16.58061 8.29031
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ferritin
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Milda.
0
50
100
150
200
250
300
350
400
Anemia of Chronic Disese Iron Defeciency Anemia
354.4
20.25
Mean FERRITIN
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MEAN FERRITIN IN MODERATE LV DYSFUNCTION:
MEAN FERRITIN
Group Statisticsa
18 300.6111 132.65973 31.26820
11 138.3636 168.60977 50.83776
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ferritin
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Moderatea.
0
50
100
150
200
250
300
350
Anemia of Chronic Disese Iron Defeciency Anemia
300.6111
138.3636
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MEAN FERRITIN IN SEVERE LV DYSFUNCTION:
Group Statisticsa
8 251.7500 116.65548 41.24394
4 17.2500 2.21736 1.10868
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ferritin
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Severea.
0
50
100
150
200
250
300
Anemia of Chronic Disese Iron Defeciency Anemia
251.75
17.25
Mean FERRITIN
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MEAN TIBC:
Group Statistics
31 200.1613 117.75344 21.14914
19 466.4737 155.97306 35.78267
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
TIBC
N Mean Std. Deviation
Std. Error
Mean
200.1613
466.4737
0
50
100
150
200
250
300
350
400
450
500
Anemia of Chronic Disese Iron Defeciency Anemia
Mean TIBC
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MEAN TIBC IN MILD LV DYSFUNCTION:
Group Statisticsa
5 211.0000 97.02577 43.39124
4 504.7500 12.84199 6.42099
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
TIBC
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Milda.
0
100
200
300
400
500
600
Anemia of Chronic Disese Iron Defeciency Anemia
211
504.75
Mean TIBC
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MEAN TIBC IN MODERATE LV DYSFUNCTION:
Group Statisticsa
18 189.1667 119.50843 28.16841
11 398.8182 165.29236 49.83752
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
TIBC
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Moderatea.
0
50
100
150
200
250
300
350
400
Anemia of Chronic Disese Iron Defeciency Anemia
189.1667
398.8182Mean TIBC
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MEAN TIBC IN SEVERE LV DYSFUNCTION:
Group Statisticsa
8 218.1250 136.36970 48.21397
4 614.2500 82.91512 41.45756
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
TIBC
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Severea.
0
100
200
300
400
500
600
700
Anemia of Chronic Disese Iron Defeciency Anemia
218.125
614.25
Mean TIBC
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MEAN EJECTION FRACTION:
Group Statistics
31 40.1935 8.45939 1.51935
19 42.6316 9.56388 2.19410
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ejection Fraction
N Mean Std. Deviation
Std. Error
Mean
40.1935
42.6319
38.5
39
39.5
40
40.5
41
41.5
42
42.5
43
Anemia of Chronic
Disese
Iron Defeciency
Anemia
Mean EF
Anemia of Chronic Disese
Iron Defeciency Anemia
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CRP:
Anemia of Chronic Disease:
CRP * GROUP Crosstabulation
Count
17 6 23
14 13 27
31 19 50
Positive
Negative
CRP
Total
Anemia of
Chronic
Disease
Iron
Defeciency
Anemia
GROUP
Total
0
5
10
15
20
Positive Negative
17
14
65
Iron Defeciency Anemia:
0
2
4
6
8
10
12
14
Positive Negative
6
13
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POSITIVE CRP:
Group Statisticsa
17 39.7059 10.13512 2.45813
6 45.8333 4.44597 1.81506
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ejection Fraction
N Mean Std. Deviation
Std. Error
Mean
CRP = Positivea.
17
6
0
2
4
6
8
10
12
14
16
18
Anemia of Chronic
Disese
Iron Defeciency Anemia
POSITIVE CRP
Anemia of Chronic Disese
Iron Defeciency Anemia
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NEGATIVE CRP:
Group Statisticsa
14 40.7857 6.16664 1.64810
13 41.1538 11.02154 3.05683
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Ejection Fraction
N Mean Std. Deviation
Std. Error
Mean
CRP = Negativea.
14
13
12.4
12.6
12.8
13
13.2
13.4
13.6
13.8
14
14.2
Anemia of Chronic
Disese
Iron Defeciency
Anemia
NEGATIVE CRP
Anemia of Chronic Disese
Iron Defeciency Anemia
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MEAN HEMOGLOBIN:
Group Statistics
31 10.5871 .99624 .17893
19 9.5684 .89570 .20549
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Hb
N Mean Std. Deviation
Std. Error
Mean
10.5871
9.5684
9
9.2
9.4
9.6
9.8
10
10.2
10.4
10.6
10.8
Anemia of Chronic
Disese
Iron Defeciency
Anemia
Mean HB
Anemia of Chronic Disese
Iron Defeciency Anemia
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MEAN HEMOGLOBIN IN MILD LV DYSFUNCTION:
Group Statisticsa
5 11.2400 .76354 .34147
4 9.8000 1.32916 .66458
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Hb
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Milda.
11.24
9.8
9
9.5
10
10.5
11
11.5
Anemia of Chronic
Disese
Iron Defeciency
Anemia
Mean HB
Anemia of Chronic Disese
Iron Defeciency Anemia
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MEAN HEMOGLOBIN IN MODERATE LV DYSFUNCTION:
Group Statisticsa
18 10.3889 1.06489 .25100
11 9.7364 .73386 .22127
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Hb
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Moderatea.
10.3889
9.7364
9.4
9.6
9.8
10
10.2
10.4
10.6
Anemia of Chronic
Disese
Iron Defeciency
Anemia
Mean HB
Anemia of Chronic Disese
Iron Defeciency Anemia
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MEAN HEMOGLOBIN IN SEVERE LV DYSFUNCTION:
Group Statisticsa
8 10.6250 .87137 .30808
4 8.8750 .66018 .33009
GROUP
Anemia of Chronic
Disease
Iron Defeciency Anemia
Hb
N Mean Std. Deviation
Std. Error
Mean
Severity of LVD = Severea.
8
8.5
9
9.5
10
10.5
11
Anemia of Chronic
Disese
Iron Defeciency
Anemia
10.625
8.875
Mean HB
Anemia of Chronic Disese
Iron Defeciency Anemia
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Ejection fraction in Anemia of Chronic Disease:
Severity of LVD * GROUP Crosstabulation
Count
5 4 9
18 11 29
8 4 12
31 19 50
Mild
Moderate
Severe
Severity
of LVD
Total
Anemia of
Chronic
Disease
Iron
Defeciency
Anemia
GROUP
Total
5
18
8
0
2
4
6
8
10
12
14
16
18
20
Mild Moderate Severe
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EJECTION FRACTION IN IRON DEFECIENCY ANEMIA:
0
2
4
6
8
10
12
Mild Moderate Severe
4
11
4
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DISCUSSION
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DISCUSSION:
This study was conducted in thirunelveli medical college hospital. 50
anemic  chronic heart failure cases Who were attending review op regularly
included in the study.  Among them 26 are male and 24 are female patients.
They were between age 45 and 64 years. They were known to suffer from
chronic heart failure, either systolic or diastolic dysfunction. Male with
haemoglobin <13 g/dl and female with values <12 g/dl were selected. They
were all clinically stable without any signs of congestion. New cases of heart
failure defined by duration of less than 6 months and those with renal
dysfunction were not included in this study. They were investigated with
complete blood count, peripheral smear, renal function test, ESR, CRP,
serum ferritin and total iron binding capacity to differentiate as those having
anemia of chronic disease and iron deficiency anemia. In males, normal
ferritin value is 24 to 274 ng/ml. in female, 4.6 to 204 ng/ml. in male, normal
TIBC value is 171 to 504 micro g/dl. In female, 149 to 491 micro g/dl. In
anemia of chronic disease, ferritin will be normal or increased and TIBC will
be low or normal. In iron deficiency anemia, ferritin will be low and TIBC
will be high.
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In this study, among the 50 cases 31 had anemia of chronic disease
and 19 had iron deficiency anemia. In the anemia of chronic disease group,
16 were male and 15 were female. Among the iron deficiency anemia group,
10 were male and 9 were female. Mean ferritin level among anemia of
chronic disease was 296.68 and 88 in anemia of chronic disease group. Mean
TIBC were 200.16 and 466.47 among these groups respectively. CRP was
positive in 17 cases of anemia of chronic disease and 6 among iron
deficiency anemia cases. CRP was negative in 14 cases of anemia of chronic
disease and 13 cases of iron deficiency anemia cases. Mean ejection fraction
in anemia of chronic disease was 40.19 and 42.63 in iron deficiency anemia
group. In patients with mild LV dysfunction, 5 were in anemia of chronic
disease group and 4 in iron deficiency anemia group. In moderate LVD
group, it was 18 and 11 respectively. In severe LVD group, it was 8 and 4
respectively.
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CONCLUSION
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CONCLUSION:
From my study I found out that
 The anemia of chronic disease is more prevalent than iron deficiency
anemia in chronic heart failure patients.
 With increasing severity of LV dysfunction the prevalence of anemia
of chronic disease is more than that of iron deficiency anemia.
 In some disease reversal will correct the anemic state
 In chronic cases supportive management is to be given for better
prognosis
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ANNEXURES
ANNEXURE – 1
PROFORMA
Patient name: Age:
Address:
Review OP No:
Medical history:
Clinical findings:
Complete blood count:
Peripheral smear study:
Renal function test:
ESR:
CRP:
Iron study:
Serum ferritin                      :
Total iron binding capacity:
ANNEXURE – 2
MASTER CHART
S.N
O
NAME AGE SEX HEMO
GLOBIN
G/DL
C
R
P
FERRITIN
NG/ML
TIBC
MICRO
G/ML
PERIPHERAL SMEAR
1 RAJAMMAL 48 FEMALE 10.2 + 316 150 NORMOCYTIC
NORMOCHROMIC
2 GURUVAMMAL 57 FEMALE 9.2 - 250 125 NORMOCYTIC
NORMOCHROMIC
3 GNANAM 54 FEMALE 8.4 + 389 105 NORMOCYTIC
NORMOCHROMIC
4 DURAIPANDI 60 MALE 11.6 - 256 150 NORMOCYTIC
NORMOCHROMIC
5 MURUGAN 56 MALE 11 - 20 515 MICROCYTIC
HYPOCHROMIC
6 PETER 63 MALE 10.2 - 42 490 MICROCYTIC
HYPOCHROMIC
7 IQBAL 57 MALE 9.2 - 18 612 MICROCYTIC
HYPOCROMIC
8 GANAPATHY 62 MALE 10.5 + 52 610 MICROCYTIC
HYPOCHROMIC
9 SIDHANADHAN 53 MALE 10.6 + 25 516 MICROCYTIC
HYPOCHROMIC
10 GUHAN 48 MALE 8.1 - 16 718 MICROCYTIC
HYPOCHROMIC
11 MOHAN 54 MALE 10.8 - 318 160 MICROCYTIC
HYPOCHROMIC
12 KARUPASAMY 48 MALE 11.4 - 220 152 NORMOCYTIC
NORMOCHROMIC
13 SUDALAI 63 MALE 10 + 324 220 MICROCYTIC
HYPOCHROMIC
14 MAYANDI 48 MALE 10.8
-
368 120 NORMOCYTIC
NORMOCHROMIC
15 ALAGU 48 FEMALE 10.8 + 316 79 NORMOCYTIC
NORMOCHROMIC
16 MUTHALAGI 57 FEMALE 11 + 258 160 NORMOCYTIC
NORMOCHROMIC
17 SUSAIAMMA 47 FEMALE 8.9 - 150 132 NORMOCYTIC
NORMOCHROMIC
18 KANI 53 FEMALE 10.6 + 460 78 NORMOCYTIC
NORMOCHROMIC
19 ARUNACHALA
M
60 MALE 12 - 200 348 NORMOCYTIC
NORMOCHROMIC
20 KATHIR 53 MALE 11.1 - 243 180 NORMOCYTIC
NORMOCHROMIC
21 MUNIYASAMY 59 MALE 8.6 - 20 612 MICROCYTIC
HYPOCHROMIC
22 RAJAIAH 49 MALE 9.1 - 32 570 MICROCYTIC
HYPOCHROMIC
23 MANIMUTHU 58 MALE 10.8 - 10 502 NORMOCYTIC
NORMOCHROMIC
24 GURUVAMMAL 60 FEMALE 9.1 + 105 482 MICROCYTIC
HYPOCHROMIC
25 STELLA 58 FEMALE 9.6 - 15 515 MICROCYTIC
HYPOCHROMIC
26 ARULAMUDHU 51 FEMALE 8.5 - 18 350 MICROCYTIC
HYPOCHROMIC
27 MANGAI 48 FEMALE 9.5 - 4 562 MICROCYTIC
HYPOCHROMIC
28 THANGAM 54 FEMALE 10.1 - 16 498 MICROCYTIC
HYPOCHROMIC
29 PALAVESAM 52 MALE 11 + 4.2 521 NORMOCYTIC
NORMOCHROMIC
30 MAHESWARI 57 FEMALE 9.4 - 162 289 MICROCYTIC
HYPOCHROMIC
31 MUTHU 54 FEMALE 7.9 - 2 516 NORMOCYTIC
NORMOCHROMIC
32 KATHAYI 49 FEMALE 9.6 + 156 359 MICROCYTIC
HYPOCHROMIC
33 SEIKAMMAL 61 FEMALE 10.7 - 78 356 MICROCYTIC
HYPOCHROMIC
34 JACOB
SELVARAJ
58 MALE 11.2 + 460 210 NORMOCYTIC
NORMOCHROMIC
35 MUNIYAMMAL 62 FEMALE 8.9 + 492 52 NORMOCYTIC
NORMOCHROMIC
36 PONNAIAH 63 MALE 11 + 224 250 NORMOCYTIC
NORMOCHROMIC
37 SUDHA 58 FEMALE 10.4 - 250 280 NORMOCYTIC
NORMOCHROMIC
38 ROSAMMAL 49 FEMALE 11 - 280 156 NORMOCYTIC
NORMOCHROMIC
39 SUDALI 53 FEMALE 10.8 158 130 NORMOCYTIC
NORMOCHROMIC
40 MUMTAZ 52 FEMALE 9.8 + 465 89 NORMOCYTIC
NORMOCHROMIC
41 THAYI 61 FEMAL
E
9.8 - 216 280 NORMOCYTIC
NORMOCHROMIC
42 SAMSUDHEEN 63 MALE 9.8 + 520 186 NORMOCYTIC
NORMOCHROMIC
43 JEYAPAL 62 MALE 12 + 350 280 NORMOCYTIC
NORMOCHROMIC
44 MANIRAJ 50 MALE 12.2 - 350 298 NORMOCYTIC
NORMOCHROMIC
45 KRISHNAN 59 MALE 9.6 + 330 88 MICROCYTIC
HYPOCHROMIC
46 PERUMAL 55 MALE 11.5 + 352 276 NORMOCYTIC
NORMOCHROMIC
47 NAGARAJ 46 MALE 12.1 - 258 321 NORMOCYTIC
NORMOCHROMIC
48 ARUMUGAM 52 MALE 10.5 + 560 205 MICROCYTIC
HYPOCHROMIC
49 CHELLAIAH 56 MALE 10.5 + 424 220 NORMOCYTIC
NORMOCHROMIC
50 VADIVU
SUNDARAM
62 MALE 9.2 + 316 116 NORMOCYTIC
NORMOCHROMIC
ANNEXURE – 3
ABBREVIATIONS
ESR - Erythrocyte sedimentation rate
CRP - C reactive protein
TIBC - total iron binding capacity
CHF - congestive heart failure
HB - hemoglobin
RDW - red cell distribution width
EPO - erythropoietin
CKD - chronic kidney disease
